Videos
March 23, 2021
Jonathan Rosenberg, MD, discusses results from a phase 3 trial comparing enfortumab vedotin and chemotherapy in locally advanced or metastatic urothelial carcinoma.
Podcast
March 23, 2021
Nataliya Mar, MD, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer.
Videos
March 19, 2021
Stephanie Wheeler, PhD, MPH, discusses results from a study focusing on patterns and predictors of oral anticancer agent utilization in metastatic RCC.
Videos
March 19, 2021
Alicia Morgans, MD, MPH, discusses results from study which examined treatment patterns among patients with metastatic urothelial carcinoma previously treated with PD-1/L1 inhibitor therapy.
Videos
March 18, 2021
Daniel Geynisman, MD, discusses treatment patterns and sequences in real-world patients with metastatic RCC after first line nivolumab plus ipilimumab or sunitinib monotherapy.
Videos
March 18, 2021
Ravi Jayadevappa, PhD, MS, discusses results from a study that examined the association between hospital competition, quality, and cost of prostate cancer care among Medicare fee-for-service beneficiaries.
Videos
March 12, 2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Conference Coverage
March 03, 2021
Patients with prostate cancer who were non-adherent to advanced oral therapies experienced substantially higher HCRU than those who were adherent.
Videos
February 26, 2021
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition with cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Videos
February 25, 2021
Michaela Dinan, PhD, discusses results from a study which investigated real-world adherence and outcomes associated with oral anticancer agent use in patients with metastatic RCC.
Videos
February 25, 2021
Ravi Jayadevappa, PhD, MS, discusses the association between hospital efficiency and quality of care in African American, Hispanic, and white Medicare beneficiaries with prostate cancer.
Videos
February 21, 2021
Ajeet Gajra, FACP, MD, discusses differences in referral patterns and treatment preferences between medical oncologists and urologists for patients with advanced prostate cancer.
Conference Coverage
February 21, 2021
Among patients with metastatic castration-sensitive prostate cancer, apalutamide plus ADT improves OS with a significant reduction in risk of death.
Videos
February 19, 2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Videos
February 19, 2021
David Gill, MD, discusses the incidence and cost of radical prostatectomy for NCCN low-risk prostate cancer in the state of Utah.
Videos
February 19, 2021
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Videos
February 19, 2021
Shilpa Gupta, MD, discusses patient characteristics and survival outcomes by PTEN loss of function status among patients with metastatic CRPC in real-world practice.
Conference Coverage
February 18, 2021
Apalutamide added to abiraterone acetate plus prednisone improves radiographic PFS by 7.4 months vs abiraterone acetate plus prednisone alone in metastatic castration-resistant prostate cancer.
Videos
February 18, 2021
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Videos
February 18, 2021
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Conference Coverage
February 16, 2021
Results from a real-world study highlight the clinical and resource utilization burden of adverse events among patients with prostate cancer treated with apalutamide and enzalutamide.
Conference Coverage
February 16, 2021
Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.
Videos
February 15, 2021
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.
Videos
February 13, 2021
Fred Saad, MD, discusses final results from the phase 3 ACIS trial, which compared apalutamide vs placebo in combination with abiraterone acetate plus prednisone in metastatic CRPC.